Frontier research · Las Vegas

Drug discovery from first principles.

We’re a research company using AI-assisted, novel mathematics to find new angles on medicine’s oldest problems.

Fig. 01 Intact
IllustrativeSame molecule, different question. A new description of a problem opens angles that brute force never reaches.
01 The problem

Most drugs are designed the same way: find a protein, build a key to fit its lock.

It’s slow, it’s expensive, and it breaks down when the target mutates, hides or has no lock at all. The usual answer is more of the same: more compounds, more compute, more trials.

Infection
Virusesevolve around their drugs.
Resistance
Bacteriabuild resistance.
Oncology
Cancersrewire themselves.
Neurology
Misfolded proteinsin Alzheimer’s and Parkinson’s have resisted decades of effort.
02 Our approach

We don’t brute-force biology.

The standard playbook is scale: screen more molecules, train bigger models on past drugs, and hope something fits. We take a different posture. We work at the frontier of mathematics, with AI as an instrument, to describe disease in terms no one has written down before. A new description gives a new angle, and new angles are how old problems finally move.

Brute force asks
How many more molecules can we screen?
We ask
What question hasn’t anyone thought to compute?
Novel mathematics

New descriptions, not bigger searches.

When a problem has resisted decades of effort, we assume the description is the bottleneck, and we go looking for a better one.

AI-assisted

AI as an instrument, not an oracle.

We use AI to explore, check and accelerate the work, while our models stay grounded in physics and mathematics rather than in pattern-matching on the past.

One foundation

One way of thinking, every program.

The same foundations serve neurology, infection and oncology. Moving into a new disease area means asking a new question, not building a new company.

03 Research programs

Five programs. One central question each.

01

Neurodegeneration

Can we take aggregates apart, instead of slowing their spread?

We’re targeting the protein clumps behind Alzheimer’s, Parkinson’s, ALS and prion disease.

Protein aggregationBiophysicsAlzheimer’sParkinson’sALSPrion
02

Broad-spectrum antivirals

Can one mechanism work across virus families?

Instead of fighting one strain at a time, we’re looking for a mechanism that isn’t tied to any single viral protein, so a mutation alone can’t get around it.

VirologyCross-family
03

Next-generation antibiotics

What can’t a bacterium give up without dying?

We’re aiming at exactly that, to close off the usual route to resistance.

MicrobiologyAntimicrobial resistance
04

Precision oncology

Which patients will respond, before treatment begins?

We’re working to match therapy to the individual tumor, instead of to the average patient.

Tumor evolutionResponse prediction
05

Molecular targeting

Where exactly is a structure weakest?

We’re mapping that point precisely, so a drug can act where it does the most good with the least collateral damage.

Structural mathematicsSelectivity
04 Our home

Proudly building in Las Vegas.

Every world-class hub started somewhere. Silicon Valley was orchards once. It took a few people who decided not to wait for permission.

Why not us.
Why not here.
Why not now.

06 Where we are

Early, deliberate, and building toward the lab.

Computational discoveryNow
Laboratory validationBuilding partnerships

New angles on age-old problems.

For investors, research labs and collaborators who want to test a different starting point for drug discovery.

[email protected] →